What are the recent news and events about RVMD?
Revolution Medicines has experienced significant clinical and corporate developments, highlighted by regulatory milestones for its core oncology pipeline. The U.S. Food and Drug Administration accepted its New Drug Application for daraxonrasib for priority review targeting previously treated metastatic pancreatic cancer, while the European Medicines Agency granted a phased review process. Additionally, the company presented robust clinical data from advanced trials assessing its RAS(ON) inhibitor combination regimens at major international cancer congresses and scheduled its upcoming quarterly financial results webcast.
Related FAQs
Rocket Mortgage is the primary business segment of Rocket Companies, Inc., which is a publicly traded company. You can buy stock in the parent company, Rocket Companies, which is listed on the New York Stock Exchange under the ticker symbol "RKT.
Wall Street equity research analysts tracking Revolution Medicines, Inc. (NASDAQ: RVMD) maintain an overwhelmingly bullish consensus rating, with 12-month average price targets clustered around $177 to $207, and upper forecasts scaling up to $236.
Revolution Medicines Inc. is a fully public biotechnology corporation whose common stock is actively traded on the Nasdaq Global Select Market under the ticker symbol RVMD.
Rithm Capital Corp. (trading under the ticker RITM) has not executed traditional forward retail stock splits during its trading history as a prominent real estate investment trust and asset manager.
Revolution Medicines is widely regarded by biotechnology equity research analysts as an innovative, highly promising precision oncology enterprise specializing in targeted therapies for RAS-addicted cancers.
Revolution Medicines represents a compelling high-growth equity option for investors seeking specialized exposure to advanced precision oncology and targeted cancer drug development.
Wall Street equity research analysts covering Revolution Medicines, Inc.
Revolution Medicines is a specialized clinical-stage oncology company focused on developing novel targeted therapies designed to inhibit elusive frontier targets within human cancer signaling pathways.
Revolution Medicines is a clinical-stage oncology enterprise dedicated to developing specialized targeted therapies that inhibit elusive frontier targets within dynamic cellular signaling networks driving human cancers.
Revolution Medicines, designated by the ticker RVMD, enjoys a strong consensus rating of Buy from clinical-stage biotechnology and precision oncology analysts.
Revolution Medicines, Inc. officially completed its initial public offering and began trading its common stock on the NASDAQ Global Select Market under the ticker symbol RVMD on February 14, 2020.
Evaluating whether a political, social, or technological revolution is beneficial or harmful depends entirely on the historical context, underlying motivations, and long-term consequences of the movement.
Danimer Scientific (DNMR) faces significant financial challenges, having filed for voluntary reorganization under Chapter 11 bankruptcy in March 2025.
Revolution Medicines, Inc. officially completed its initial public offering and began trading its common stock on the NASDAQ Global Select Market under the ticker symbol RVMD on February 14, 2020.
Market consensus recommendations for Revolution Medicines (NASDAQ: RVMD) generally reflect favorable buy and moderate accumulation ratings among biotechnology and precision oncology equity research analysts.
Yes, you can invest in the Saudi stock market (Tadawul) as an international investor.
The abbreviation RVMD serves as the official stock ticker symbol for Revolution Medicines, Inc., which is a clinical-stage precision oncology biopharmaceutical enterprise dedicated to developing novel therapies targeting RAS-addicted cancers.
Revolution Medicines looks toward an encouraging future as a clinical-stage precision oncology enterprise focused on developing novel therapies targeting RAS-addicted cancers.
Revolution Medicines frequently attracts speculation as a potential acquisition target among major pharmaceutical conglomerates seeking to bolster their oncology pipelines with advanced targeted therapies against elusive cancer targets.